Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
REM Behavior DisorderParkinson Disease
Trial Locations (17)

11725

RECRUITING

Parkinson's Research Centers of America - Long Island, Commack

14618

RECRUITING

University of Rochester, Rochester

20832

RECRUITING

MedStar Montgomery Medical Center, Olney

30327

RECRUITING

Atlanta NeuroScience Institute ANI, Atlanta

33180

RECRUITING

Aventura Neurologic Associates, LLC, Aventura

33486

RECRUITING

Parkinson's Disease and Movement Disorders Center - Boca Raton, Boca Raton

38157

ACTIVE_NOT_RECRUITING

Veracity Neuroscience LLC, Memphis

40241

RECRUITING

Neurology Multidisciplinary Clinic at Norton Healthcare, Louisville

66160

RECRUITING

Parkinson's Disease and Movement Disorders Center at KUMC, Kansas City

78229

RECRUITING

UT Health San Antonio, San Antonio

80045

RECRUITING

University of Colorado, Aurora

85258

RECRUITING

CND Life Sciences, Scottsdale

RECRUITING

Movement Disorders Center of Arizona, Scottsdale

90048

RECRUITING

Cedars Sinai, Los Angeles

92656

RECRUITING

Parkinson's Research Centers of America - Orange County, Aliso Viejo

94301

RECRUITING

Parkinson's Research Centers of America - Palo Alto, Palo Alto

02747

RECRUITING

Boston Neuro Research Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

CND Life Sciences

OTHER

NCT06621602 - Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease | Biotech Hunter | Biotech Hunter